靶向治疗前肝转移灶CT衰减值可预测结直肠癌患者总生存:随机开放标签FIRE-3/AIO KRK0306试验结果
基于FIRE-3随机III期试验中347例可评估肝转移灶的mCRC患者,回顾性半自动体积测量基线门静脉期CT肝转移灶平均衰减值。衰减值每增加10 HU与OS延长相关(HR 0.85),≥61.62 HU阈值与更长OS(中位21.3 vs 30.6个月;HR 0.61)及更好肿瘤反应相关。
要点
- 基线CT肝转移灶平均衰减值≥61.62 HU提示更长OS(中位21.3 vs 30.6个月;HR 0.61)。
- 衰减值每增加10 HU,OS风险降低(HR 0.85,95%CI 0.78-0.93,p<0.001)。
- 高衰减值还与更明显的早期肿瘤缩小(p=0.002)和更深缓解(p=0.012)相关。
核心结论
- 基线CT肝转移灶平均衰减值升高可能识别出OS延长且肿瘤反应更好的mCRC患者。
研究设计与样本
- 随机、开放标签、前瞻性III期FIRE-3试验的子分析;592例入组,347例可评估肝体积测量;基线门静脉期CT(层厚≤5 mm)半自动体积测量肝转移灶平均衰减值。
关键影像表现/征象
- 肝转移灶基线CT平均衰减值中位数59.67 HU(IQR 49.13-68.85 HU)。
- 衰减值每增加10 HU与OS延长相关(HR 0.85,95%CI 0.78-0.93,p<0.001)。
- 阈值≥61.62 HU与OS延长相关(中位21.3 vs 30.6个月;HR 0.61,95%CI 0.47-0.80,p<0.001)。
- 多因素回归校正相关及进一步预后因素后结果仍成立(HR 0.60,95%CI 0.45-0.81,p=0.001)。
- 平均衰减值≥61.62 HU与早期肿瘤缩小增加(p=0.002)和缓解深度增加(p=0.012)显著相关。
诊断标准与关键数值
- 基线肝转移灶平均CT衰减值最佳阈值为≥61.62 HU,用于识别OS延长(p<0.001)、早期肿瘤缩小(p=0.002)和缓解深度增加(p=0.012)。
- 衰减值每增加10 HU的OS风险比HR 0.85(95%CI 0.78-0.93,p<0.001)。
- 阈值≥61.62 HU的OS风险比HR 0.61(95%CI 0.47-0.80,p<0.001),多因素校正后HR 0.60(95%CI 0.45-0.81,p=0.001)。
临床应用与阅片要点
- 基线门静脉期CT(层厚≤5 mm)上半自动体积测量肝转移灶平均衰减值,可作为mCRC患者预后评估的参考指标。
- 平均衰减值≥61.62 HU可能提示更长的OS和更好的肿瘤反应。
局限性
- 肝转移灶CT衰减值为回顾性评估。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess the prognostic value of pre-therapeutic computed tomography (CT) attenuation of liver metastases for overall survival (OS) in metastatic colorectal cancer (mCRC).
METHODS: In the open-label, randomised, prospective phase-III FIRE-3 trial, patients with histologically confirmed mCRC received fluorouracil (5-FU), leucovorin and irinotecan (FOLFIRI) with either cetuximab or bevacizumab. Participating patients gave written informed consent prior to study entry. In CT at baseline (portal venous phase, slice thickness ≤5 mm), mean attenuation [Hounsfield units (HU)] of liver metastases was retrospectively assessed by semi-automated volumetry. Its prognostic influence on OS was analysed in Kaplan-Meier-analysis and Cox proportional hazard regression and an optimal threshold was determined.
RESULTS: In FIRE-3, 592 patients were enrolled between 2007 and 2012. Among the 347 patients eligible for liver volumetry, median baseline CT attenuation of liver metastases was 59.67 HU [interquartile range (IQR), 49.13, 68.85]. Increased attenuation was associated with longer OS {per 10 HU: hazard ratio (HR), 0.85 [95% confidence interval (CI), 0.78, 0.93], p < 0.001}. The optimised threshold (≥61.62 HU) was a strong predictor for increased OS [median, 21.3 vs 30.6 months; HR, 0.61 (95% CI, 0.47, 0.80), p < 0.001]. Multivariate regression controlling for correlated and further prognostic factors confirmed this [HR, 0.60 (95% CI, 0.45, 0.81), p = 0.001]. Furthermore, mean attenuation ≥61.62 HU was significantly associated with increased early tumour shrinkage (p = 0.002) and increased depth of response (p = 0.012).
CONCLUSIONS: Increased mean baseline CT attenuation of liver metastases may identify mCRC patients with prolonged OS and better tumour response.
KEY POINTS: • In colorectal cancer, increased attenuation of liver metastases in baseline computed tomography is a prognostic factor for prolonged OS (p < 0.001). • A threshold of ≥61.62 HU was determined as optimal cut-off to identify patients with prolonged OS (p < 0.001), early tumour shrinkage (p = 0.002) and increased depth of response (p = 0.012).
引用
- Froelich MF, Heinemann V, Sommer WH, et al. CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial. Eur Radiol. 2018. PMID: 29882070. doi:10.1007/s00330-018-5454-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。